{
    "title": "109_hr870",
    "content": "The Act may be cited as the Pharmaceutical Research and Manufacturers Accountability Act of 2005 or the PhRMA Act of 2005. It addresses the concealment of serious adverse drug experiences. The Pharmaceutical Research and Manufacturers Accountability Act of 2005, also known as the PhRMA Act of 2005, introduces penalties for knowing concealment of serious adverse drug experiences. This includes imprisonment for a minimum of 20 years and a maximum of life, a fine of up to $2,000,000, or both, for individuals in senior positions at drug manufacturers who knowingly conceal evidence of serious adverse drug experiences. Additionally, CEOs are required to provide an annual attestation regarding any serious adverse drug experiences. The Federal Food, Drug, and Cosmetic Act is amended to require CEOs of drug manufacturers to submit an annual attestation disclosing any serious adverse drug experiences related to their products. The term 'evidence of any serious adverse drug experience' includes information obtained from various sources such as clinical trials, postmarketing surveillance, and reports by physicians, as required by the Act. The term 'serious adverse drug experience' refers to adverse drug events that result in death, life-threatening situations, hospitalization, disability, or birth defects. The Secretary will mandate initial attestation for such events. The Secretary mandates initial attestation for serious adverse drug experiences, requiring timely submission from drug manufacturers to maintain approval. Failure to submit may result in approval withdrawal. The Secretary may withdraw approval of an application if necessary, pending a safety review of the drug and reimbursement of review costs by the manufacturer. Additional information on drug safety may be requested during the review process. The Federal Food, Drug, and Cosmetic Act is amended to include fines for failing to submit an attestation in accordance with section 505(o). Violators may be fined up to $1,000,000, with each 30-day period of violation considered a separate offense. Additionally, there is a deadline for postmarketing studies under section 505 of the Act. The Federal Food, Drug, and Cosmetic Act is amended to include fines for failing to complete postmarketing studies by the deadline set by the Secretary under section 505(p). The Federal Food, Drug, and Cosmetic Act is amended to include fines for failing to complete postmarketing studies by the deadline set by the Secretary under section 505(p). Violators may be fined up to $5,000,000 for each 30-day period of non-compliance. The CEO of a drug manufacturer or any individual may be fined under the amendments made by this Act."
}